Evidence map›Paper›PMID 37309002›Full record

ArticleBMC health services research2023

Knowledge support for environmental information on pharmaceuticals: experiences among Swedish Drug and Therapeutics Committees.

Elkanah Linder, Björn Wettermark, Marie-Louise Ovesjö, Sofia Kälvemark Sporrong, Helena Ramström

Abstract read
In one paragraph

Article in BMC health services research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. The Potential Role of Ecotoxicological Data in National Essential Medicine Lists: A Cross-Sectional Analysis.International journal of environmental research and public health · 2025
    Article
  5. Article
  6. A Formulary Management Group Consensus.Global journal on quality and safety in healthcare · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elkanah LinderPharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden. elkanah.linder@farmaci.uu.se.ORCID http://orcid.org/0000-0002-6470-2939
Björn WettermarkPharmacoepidemiology, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-0531-2516
Marie-Louise OvesjöDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0591-6208
Sofia Kälvemark SporrongSocial Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0001-5848-8625
Helena RamströmHealth and Medical Care Administration, Region Stockholm, Sweden.ORCID http://orcid.org/0000-0002-5093-6136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTwo publicly available Swedish knowledge support systems, "Pharmaceuticals and Environment" on Janusinfo.se and Fass.se, provide environmental information on pharmaceuticals. Janusinfo is provided by the public healthcare system in Stockholm and Fass is provided by the pharmaceutical industry. The objectives of this study were to investigate the experiences among Swedish Drug and Therapeutics Committees (DTCs) with using the databases, retrieve development proposals for these, and investigate the DTCs' challenges with working with pharmaceuticals in the environment.

methodsA cross-sectional survey with 21 questions, both closed and open-ended, was distributed electronically in March 2022 to Sweden's 21 DTCs. Descriptive statistics and inductive categorization were used for the analysis.

resultsA total of 132 respondents from 18 regions filled out the survey. The average regional response rate was 42%. The DTCs used the knowledge supports to consider environmental aspects of pharmaceuticals in their formularies and in education. Respondents were more familiar with Janusinfo compared to Fass but appreciated the availability of both. The DTCs especially valued the concrete proposals for certain active pharmaceutical ingredients on Janusinfo. Respondents requested that all medicinal products have environmental information on Fass. Challenges included lack of data, lack of transparency from the pharmaceutical industry and difficulties considering the environmental aspect of pharmaceuticals in their healthcare practice. Respondents wanted more knowledge, clear messages, and legislation to support their work to reduce the negative environmental impact of pharmaceuticals.

conclusionsThis study demonstrates that knowledge supports for environmental information on pharmaceuticals are valuable for the DTCs in Sweden, but the respondents experienced challenges in their work in this field. The study can provide insights to those in other countries interested in considering environmental aspects in their formulary decision-making.

Indexed as

DitiocarbPharmacy and Therapeutics CommitteeCross-Sectional StudiesDatabases, FactualHumansPharmaceutical PreparationsSwedenDitiocarbPharmaceutical PreparationsDrug and Therapeutics CommitteesEnvironmentKnowledge supportPharmaceuticalsRecommended medicinesSurvey

Identifiers

PMID37309002
PMCPMC10259041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.